A Randomized Trial of Temsirolimus Versus Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy.
Phase of Trial: Phase III
Latest Information Update: 02 Dec 2013
At a glance
- Drugs Temsirolimus (Primary) ; Sorafenib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms INTORSECT
- Sponsors Pfizer; Wyeth
- 02 Dec 2013 Results published in the Journal of Clinical Oncology.
- 03 Jul 2013 Planned number of patients changed from 501 to 508 as reported by German Clinical Trials Register.
- 03 Jul 2013 New source identified and integrated (German Clinical Trials Register, DRKS00004149).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History